

## Safety Data Sheet



Bristol-Myers Squibb Company

<b>1. IDENTIFICATION</b>													
<i>Product Information</i>													
Product name	Etopophos for Injection												
Version	1.0, 06.03.2015												
Jurisdiction	This Safety Data Sheet was prepared in accordance with the Globally Harmonized System of Classification and Labelling of Chemicals (GHS) for the United States of America (USA) (CFR 1910.1200), European Union (EU) (EC 1272/2008) and United Nations (UN). The following countries utilize the UN GHS classification process: Mexico, Brazil, China, New Zealand, Canada, Japan, Korea and Australia.												
Synonyms	Etoposide Phosphate For Injection; BMY 40481 for Injection												
Intended Uses	This material is a finished drug product for patient use. It is used in the treatment of cancer.												
<i>Company/Undertaking Identification</i>													
Address	<table style="width: 100%; border: none;"> <tr> <td style="width: 33%;"><u>USA</u></td> <td style="width: 33%;"><u>Ireland</u></td> </tr> <tr> <td><b>Bristol-Myers Squibb Company</b></td> <td><b>Bristol-Myers Squibb Company</b></td> </tr> <tr> <td>P.O. Box 191</td> <td>Swords Laboratories, Watery Lane</td> </tr> <tr> <td>New Brunswick, New Jersey 08903</td> <td>Swords, Ireland</td> </tr> <tr> <td>United States of America</td> <td>MG-GBS-MSDS-Request@bms.com</td> </tr> <tr> <td>1-800-332-2056</td> <td>353-1813-9456</td> </tr> </table>	<u>USA</u>	<u>Ireland</u>	<b>Bristol-Myers Squibb Company</b>	<b>Bristol-Myers Squibb Company</b>	P.O. Box 191	Swords Laboratories, Watery Lane	New Brunswick, New Jersey 08903	Swords, Ireland	United States of America	MG-GBS-MSDS-Request@bms.com	1-800-332-2056	353-1813-9456
<u>USA</u>	<u>Ireland</u>												
<b>Bristol-Myers Squibb Company</b>	<b>Bristol-Myers Squibb Company</b>												
P.O. Box 191	Swords Laboratories, Watery Lane												
New Brunswick, New Jersey 08903	Swords, Ireland												
United States of America	MG-GBS-MSDS-Request@bms.com												
1-800-332-2056	353-1813-9456												
Emergency Phone No.	<table style="width: 100%; border: none;"> <tr> <td style="width: 33%;">USA (also Canada, Puerto Rico and the Virgin Island): 1-800-424-9300</td> <td style="width: 33%;"><u>Ireland</u>: 353-1813-9456</td> </tr> <tr> <td colspan="2" style="text-align: center;">Other Countries: See "Section 16" for country-specific emergency phone numbers from CHEMTREC.</td> </tr> </table>	USA (also Canada, Puerto Rico and the Virgin Island): 1-800-424-9300	<u>Ireland</u> : 353-1813-9456	Other Countries: See "Section 16" for country-specific emergency phone numbers from CHEMTREC.									
USA (also Canada, Puerto Rico and the Virgin Island): 1-800-424-9300	<u>Ireland</u> : 353-1813-9456												
Other Countries: See "Section 16" for country-specific emergency phone numbers from CHEMTREC.													

<b>2. HAZARDS IDENTIFICATION</b>	
<b>Classification and Labelling Common to All Jurisdictions</b>	
Classification	Germ Cell Mutagenicity - Category 1B Carcinogenicity - Category 1A Toxic To Reproduction - Male Reproductive Toxicity - Category 1A Toxic To Reproduction - Developmental Toxicity - Category 1A Specific Target Organ Systemic Toxicity (Repeated Exposure) - Category 1
Symbol	
Signal Word	Danger
Hazard Statements	May cause genetic defects. May cause cancer. May damage fertility (male reproductive toxicity) . May damage the unborn child (developmental toxicity) . Causes damage to organs (bone marrow, gastrointestinal tract, peripheral nervous system, lymphatic system, cardiovascular system, female reproductive organs, male reproductive organs) through prolonged or repeated exposure.

**2. HAZARDS IDENTIFICATION**

Precautionary Statements	Do not breathe dust. Obtain special instructions before use. Do not handle until all safety precautions have been read and understood. Use personal protective equipment as required. Wash thoroughly after handling. Do not eat, drink or smoke when using this product.
<b>Classification and Labelling for Specific Jurisdictions</b>	
<b>USA</b>	
Classification	Toxic To Reproduction - Female Reproductive Toxicity - Category 1A
Hazard Statements	May damage fertility (female reproductive toxicity) .
<b>EU</b>	
Classification	Toxic To Reproduction - Female Reproductive Toxicity - Category 1B
Hazard Statements	May damage fertility (female reproductive toxicity) .
<b>UN</b>	
Classification	Toxic To Reproduction - Female Reproductive Toxicity - Category 1A
Hazard Statements	May damage fertility (female reproductive toxicity) .

**3. COMPOSITION/INFORMATION ON INGREDIENTS**

Components	Concentration	CAS No.	EU only		
			EC No./REACH Registration No.	Symbol(s)/R-phrases)	H-code(s)
<i>Hazardous components</i>					
Etoposide Phosphate	25.5 %	117091-64-2	--	T, F: R11, R22, R45, R46, R48, R60, R61	H228 H302 H340 H350 H360F H360D H372
<i>Other ingredients</i>					
Non-Hazardous Ingredients	< 75 %	Not available	--	--	--
See section 16 for Symbol, R-phrases and H-code text.					

**4. FIRST AID MEASURES**

Eye contact	Rinse immediately with plenty of water for at least 15 minutes. Keep eye wide open while rinsing. If exposed or concerned: Get medical attention/advice.
Skin contact	Take off contaminated clothing and shoes immediately. Wash off immediately with plenty of water for at least 15 minutes. Discard contaminated clothing or wash before re-use. If exposed or concerned: Get medical attention/advice.
Inhalation	Move to fresh air. Oxygen or artificial respiration if needed. If exposed or concerned: Get medical attention/advice.
Ingestion	Do NOT induce vomiting. Never give anything by mouth to an unconscious person. If exposed or concerned: Get medical attention/advice.
Notes to Physician	Medical conditions aggravated include: disorders affecting target organs. This product has been reported to interact with the following medications: cytotoxic and cytostatic medicines, cyclosporine. Refer to Section 11. May cause harm to unborn child.
Medical Surveillance	The need for a pre-placement physical examination and history for employees with potential exposure to this compound is to be evaluated by a physician that is thoroughly knowledgeable about both the toxicity of this compound and the extent of work place exposure. Baseline testing would include: a complete blood count with differential, a blood test for liver function, EKG. Based on opportunity for exposure and duration of exposure a periodic follow-up examination may be considered. This exam should be overseen by a physician thoroughly knowledgeable about both the toxicity of this compound and the extent of work place exposure. It is recommended that the content be similar to the pre-placement exam. Employees who are pregnant, are breast-feeding, or who are concerned with other reproductive issues should be encouraged to consult with the occupational health physician monitoring worker's health.

**5. FIRE-FIGHTING MEASURES**

Flammable Properties	Not available
Extinguishing Media	Suitable extinguishing media: Dry chemical, Water spray, Foam Unsuitable extinguishing media: Do NOT use water jet.
Protection of Firefighters	Specific hazards: Not available Protective equipment: Use personal protective equipment. In the event of fire, wear self-contained breathing apparatus. Hazardous Combustion Products: carbon oxides (COx), nitrogen oxides (NOx), oxides of phosphorus, sodium oxides
Other information	Decontaminate protective clothing and equipment before reuse.

**6. ACCIDENTAL RELEASE MEASURES**

Personal precautions	Refer to protective measures listed in sections 7 and 8. Use personal protective equipment. Examples include tightly fitting safety goggles, lab coat and impervious gloves. Wear respiratory protection. Depending on the nature of the spill (quantity and extent of spill) additional protective clothing and equipment such as a self-contained breathing apparatus may be needed.
Environmental precautions	Prevent release to drains and waterways. Prevent release to the environment.
Containment Methods	Wet down any dust to prevent generation of aerosols, if appropriate. Cover with suitable material.

**6. ACCIDENTAL RELEASE MEASURES**

Cleanup Methods	Contain and collect spillage and place in container for disposal according to local regulations (see Section 13). Use a HEPA vacuum or moisten materials to minimize dust generation during pick-up. Clean area with detergent and water after spill pick-up, if appropriate. Handle waste materials, including gloves, protective clothing, contaminated spill cleanup material, etc., as appropriate for chemically and pharmacologically similar materials.
-----------------	--

**7. HANDLING AND STORAGE**

Handling Precautions	Avoid exposure - obtain special instructions before use. Avoid formation of dust and aerosols. Keep away from heat and sources of ignition. Prevent release to drains and waterways.
Container Requirements	Store in the original primary packaging as provided. Store in spill containment pallet or other device to confine spills.
Storage Conditions	Store at room temperature. Protect against light. Keep away from heat, sparks and flames. Store locked up.
Specific use(s)	Refer to Section 1

**8. EXPOSURE CONTROLS / PERSONAL PROTECTION**

Exposure limit(s)	Company Guideline	ACGIH	Germany OEL	UK MEL
Etoposide Phosphate	0.14 µg/m <sup>3</sup>	--	--	--
Recommended Industrial Hygiene Monitoring Methods	Contact the Bristol-Myers Squibb AIHA accredited Industrial Hygiene Laboratory at (USA) 732-227-6338.  General - The health hazard risk of handling this material is dependent on many factors, including physical form, % API in material being handled, duration and frequency of process task, and effectiveness of controls. If it is necessary to handle this compound outside of engineering controls, an exposure risk assessment should be conducted and procedures documented by a qualified EHS professional.			

**EXPOSURE CONTROLS / PERSONAL PROTECTION FOR MATERIAL AS SUPPLIED**

This formulation contains an active pharmaceutical ingredient (API) with the guideline limit noted above. To keep the API below the recommended guideline, the material as supplied should be controlled during handling to limit total airborne aerosol exposure to: 0.5 µg/m<sup>3</sup>.

**8. EXPOSURE CONTROLS / PERSONAL PROTECTION**

Engineering Controls and Ventilation	<p>FOR MANUFACTURING PROCESSES (BULK): Use process enclosures, containment technology, or other engineering controls to keep airborne levels below recommended exposure limit. When handling quantities up to 15 milligrams, a standard laboratory with general laboratory dilution ventilation (e.g. 6-12 air changes per hour) is appropriate. When handling quantities from 15 milligrams to 1 kilogram, work in a standard laboratory using a fume hood, biological safety cabinet(Class II, all types), or approved vented enclosure. Quantities exceeding 1 kilogram should be handled in a designated laboratory. A laminar flow/powder containment booth is recommended for handling &gt;1 kilograms of active substance. For manufacturing and pilot plant operations, use direct coupling and closed transfer systems for all bulk transfers. Use dust tight valves as appropriate. HEPA filtration of local exhaust ventilation (LEV) is required.</p> <p>FOR CLINICAL SETTING USE (DRUG PRODUCT): When handling small quantities in a clinical setting, good room ventilation is desirable. Specific engineering controls should not be needed. If significant dust is generated, use process enclosures, containment technology, or other engineering controls to keep airborne levels below recommended exposure limit. When handling broken vials or when aerosol is possible, ensure worker exposure is below the recommended exposure limit.</p>
Respiratory protection	Use and selection of respiratory protection is based upon engineering controls in use and potential for aerosol generation. When engineering controls are not sufficient to control exposure, wear an approved respirator with NIOSH Class 100 or high efficiency particulate (HEPA) filters or cartridges when exposures are up to 10 times the exposure control guideline. Wear a loose-fitting (Tyvek or helmet type) HEPA powered-air purifying respirator (PAPR) when exposures are 10-25 times the exposure control guideline. Wear a full facepiece negative pressure respirator with Class 100 or HEPA filters when exposures are 25-50 times the exposure control guideline. Wear a tight-fitting, full facepiece HEPA PAPR when exposures are 50-100 times the exposure control guideline. Wear a hood-shroud HEPA PAPR or full facepiece supplied air respirator operated in a pressure demand or other positive pressure mode when exposures are 100-1000 times the exposure control guideline.
Eye protection	Safety glasses with side-shields are recommended. Face shields or chemical safety goggles may be required if contact potential exists or if corrosive materials are present. Note: Choice of eye protection may be influenced by the type of respirator which is selected.
Hand protection	Impervious nitrile, rubber and latex gloves are recommended. If material is handled in solution, the solvent should also be considered when selecting protective clothing material. Please note that employees who are allergic to natural rubber latex should use nitrile gloves.
Skin and body protection	Wear a laboratory coat when handling quantities up to 1 kilogram. For quantities over 1 kilogram, wear laboratory coat or coverall of low permeability. For manufacturing operations, wear coverall of low permeability.
Hygiene	Wash hands and face before breaks and immediately after handling the product.
Environmental exposure controls	Prevent release to drains and waterways.

**9. PHYSICAL AND CHEMICAL PROPERTIES***General Information**Appearance*

Physical State	solid
Color	white
Form	powder, (lyophilized)

**9. PHYSICAL AND CHEMICAL PROPERTIES***Odour*

Odour	Not available
Odor Threshold	Not available

pH	2.9 (reconstituted solutions)
----	-------------------------------

*Other information*

Bulk density	Not available
Evaporation rate	Not available
Molecular formula	Not applicable
Hydrolysis/Photolysis	Not available
Hygroscopicity	Not available
Molecular Weight	Not applicable
Log Octanol/Water Partition Coefficient [log Kow]	Not available
Surface Tension	Not available
pKa	Not available
Particle Size	Not available
Solubility, Water	freely soluble
Specific Gravity/ Relative density	Not available
Viscosity, dynamic	solid
Viscosity, kinematic	Not available
% Volatile	Not available

*Thermal/Stability properties*

Autoignition temperature	Not available
Boiling Point	Not available
Thermal decomposition	Not available
Explosive Limits, LEL	Not available
Explosive limits, UEL	Not available
Explosiveness	Non-explosive based on chemical structure.
Flammability	Not available
Flash point	Not available
Melting Point	Not available
Oxidizing Potential	The compound contains oxygen, fluorine, or chlorine and these elements are not chemically bonded only to carbons or hydrogen.

*Vapor Properties*

Vapor Density	(Air =1): If adequate temperatures caused material to volatize, its vapor density would be much greater than 1. (Heavier than air)
Vapor Pressure	Not available
Saturated Vapor Concentration	Not available

**10. STABILITY AND REACTIVITY***Stability*

Chemical Stability	Stable under normal conditions.
Conditions to avoid	Not available

**10. STABILITY AND REACTIVITY**

Materials to avoid	Slightly reactive upon contact with acid reactive metals.
Hazardous decomposition products	Hazardous decomposition products formed under fire conditions.: carbon oxides (COx), nitrogen oxides (NOx), oxides of phosphorus, sodium oxides
Hazardous reactions	None known.
<i>Sensitivity to static discharge/Dust exp.</i>	
Summary Statements	Although material has not been specifically tested, fine dust suspended in air in sufficient concentration and in the presence of an ignition source may pose a potential explosion hazard. Provide appropriate bonding and grounding protection to control static charge. Powder handling equipment such as dust collectors, dryers, and mills may require additional protective measures (e.g. explosion venting, inerting, etc.).

**11. TOXICOLOGICAL INFORMATION**

Routes of Entry	Ingestion, inhalation, Eye contact, Skin contact
Eye Irritation	Not available
Skin Irritation	<u>Etoposide Phosphate</u> Mildly and/or transiently irritating to skin.
Respiratory Irritation	Not available
Sensitization	<u>Etoposide Phosphate</u> Not a dermal sensitizer in an experimental study
Acute Toxicity Study	<p><b>Acute Oral</b> <u>Etoposide Phosphate</u> LD50 (mouse, males and females): 3,800 mg/kg High exposure effects include: abnormal posture, abnormal gait, hypoactivity, labored respiration, dehydration, fecal changes.</p> <p><u>Etoposide</u> LD50 (rat): 1,784 mg/kg LD50 (rat): 1,784 mg/kg LD50 (rat): 1,784 mg/kg LD50 (rat): 1,784 mg/kg</p> <p><b>Acute toxicity (other routes of administration)</b> <u>Etoposide Phosphate</u> Maximum nonlethal dose (rat, males and females, intravenous): 31 mg/kg LD50 (mouse, males and females, intravenous): 147 mg/kg LD50 (mouse, males, intraperitoneal): 89 mg/kg</p>
Repeated Dose Toxicity	<u>Etoposide Phosphate</u> 1 months intravenous (daily) rat study with recovery period (1 months) (males and females): LOAEL = 0.15 mg/kg; Low dose effects include (<= 100 mg/kg): decreased body

**11. TOXICOLOGICAL INFORMATION**

weight, decreased food consumption, changes in clinical chemistry parameters, changes in white blood cell parameters, changes in red blood cell parameters, injection site reactions, mortality. Low dose microscopic effects include: lymphatic system, spleen, bone marrow, peripheral nervous system, male reproductive organs, gastrointestinal tract, lungs, mammary gland, heart, skin.

5 D oral (daily) mouse, rat, dog study with recovery period (30 - 60 days) (males and females): LOAEL = 3.44 mg/kg; Low dose effects include ( $\leq 100$  mg/kg): abnormal posture, dehydration, drooping eyelids, loose stools, hypoactivity, breathing difficulties, decreased body weight, decreased food consumption, tremors, decrease in body temperature, weakness, collapse, vomiting, changes in clinical pathology parameters, decreased organ weights included: thymus, testes, mortality. Low dose microscopic effects include: bone marrow, thymus, gastrointestinal tract, spleen, lymph nodes, mammary gland, testes. Effects still present after recovery include: testes.

20 D intraperitoneal (5/week) mouse, rat study with recovery period (28 - 31 D) (males): LOAEL = 2 mg/kg; Low dose effects include ( $\leq 100$  mg/kg): decreased body weight, decreased organ weights included: testes, mortality. Low dose microscopic effects include: small intestine, liver, salivary gland, spleen, thymus, bone marrow, testes.

Etoposide

1 - 3 months intravenous (daily) rat study with recovery period (2 months) (males and females): LOAEL = 0.15 mg/kg; Low dose effects include ( $\leq 100$  mg/kg): decreased body weight, decreased food consumption, changes in clinical chemistry parameters, decreased white blood cell count, changes in red blood cell parameters, injection site reactions, mortality. Low dose microscopic effects include: lymphatic system, spleen, bone marrow, peripheral nervous system, male reproductive organs, gastrointestinal tract, lungs, mammary gland, skeletal muscles. Effects still present after recovery include: testes, axonal degeneration. No mortality occurred.

## Genetic Toxicity

Etoposide**In vitro**

Ames reverse-mutation assay -- positive  
Mutagenicity (micronucleus test) -- positive  
Chromosome aberrations assay -- positive

**in vivo**

intraperitoneal, Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis) (mouse) -- positive  
intraperitoneal, mammalian germ cell cytogenetics assay (spermatogonia) (rat) -- positive

**Mutagenicity Assessment**

This material was positive in a battery of in vivo and in vitro genotoxicity assays.

## Carcinogenicity

Etoposide**Carcinogenicity Assessment**

The carcinogenic potential has not been studied. Compounds with similar mechanisms of action and mutagenic potential were reported to be carcinogenic. Some secondary cancers developed in persons with other cancers who were treated with this drug, either alone or in combination with other anticancer drugs. It is not known whether these were a result of the treatment with this drug, with one of the other drugs, or a result of progression of the underlying disease. See Human Experience. This material is probably carcinogenic to humans.



<b>11. TOXICOLOGICAL INFORMATION</b>			
<b>Carcinogenicity</b>	<b>ACGIH</b>	<b>IARC</b>	<b>NTP</b>
Etoposide Phosphate	--	1	--
Etoposide	--	2A	--
Reproductive Toxicity	<u>Etoposide</u> <b>Assessment Reproductive Toxicity</b> Animal studies indicate that reproductive effects can occur. See "Human Experience".		
Developmental Toxicity	<u>Etoposide</u> <b>Developmental Toxicity Assessment</b> This material has been shown to cross the placenta. Birth defects were observed in animal studies. This compound and/or its metabolites may be excreted into the milk. See "Human Experience".		
Human experience	<b>Experiences with Human Exposure</b> <u>Etoposide</u> General effects therapeutic use low exposure - acute effects include: nausea, vomiting, diarrhoea, loss of appetite, abdominal pain, chest pain, heart attack, congestive heart failure, hair loss, rash, nail changes, menstrual irregularities, asthma, breathing difficulties, difficulty swallowing, bruising, confusion, skin effects, eye effects, fatigue, headache, vision changes, tingling, numbness, pain, lowered blood pressure, decreased red blood cell count, decreased white blood cell count, anaphylaxis. low exposure - long term exposure effects include: colitis, acute leukemia, changes in blood clotting parameters, cardiac irregularities, inflammation of gastrointestinal tract, liver toxicity, peripheral neuropathies, ovarian changes, sperm abnormalities.		
Target Organs	<u>Etoposide Phosphate</u> bone marrow, gastrointestinal tract, peripheral nervous system, lymphatic system, cardiovascular system, female reproductive organs, male reproductive organs  <u>Etoposide</u> bone marrow, gastrointestinal tract, peripheral nervous system, lymphatic system, cardiovascular system, female reproductive organs, male reproductive organs		
Symptoms	<u>Etoposide</u> See "Human Experience".		
Pharmacokinetics/ Toxicokinetics	<u>Etoposide</u> Absorption: Not available Distribution: Not available Metabolism: Not available Elimination: Half-life = 0.6 - 10.8 Hour(s) (Human).		
Other Toxicity	Not available		

**11. TOXICOLOGICAL INFORMATION**

Information

**12. ECOLOGICAL INFORMATION**

<b>Ecotoxicity effects</b>	Not available
<b>Mobility</b>	Not available
<b>Persistence and degradability</b>	Not available
<b>PBT and vPvB assessment</b>	Not available

**13. DISPOSAL CONSIDERATIONS**

Advice On Disposal And Packaging      Disposal should be in accordance with applicable regional, national and local laws and regulations. Local regulations may be more stringent than regional or national requirements. This information presented only applies to the material as supplied.

Other information      Disposal by incineration is recommended.

**14. TRANSPORT INFORMATION**

This material is not a dangerous good for the purpose of transportation in all modes.

**15. REGULATORY INFORMATION****United States of America**

313 Toxic Release Inventory      No components listed on the SARA 313 inventory.

TSCA Inventory      Not listed.

**EU Directive 1999/45/EC**BULK MATERIAL

Symbol(s)      T: Toxic

R-phrase(s)      R22: Harmful if swallowed.  
R45: May cause cancer.  
R46: May cause heritable genetic damage.  
R48: Danger of serious damage to health by prolonged exposure.  
R60: May impair fertility.  
R61: May cause harm to the unborn child.

S-phrase(s)      S22: Do not breathe dust.  
S36/37/39: Wear suitable protective clothing, gloves and eye/face protection.  
S38: In case of insufficient ventilation, wear suitable respiratory equipment.  
S45: In case of accident or if you feel unwell, seek medical advice immediately (show label where possible).  
S53: Avoid exposure - obtain special instructions before use.  
S60: This material and its container must be disposed of as hazardous waste.

DRUG PRODUCT

Classification      Medicinal products are exempt from classification and labeling requirements under EU

**15. REGULATORY INFORMATION**

Preparations Directive 1999/45/EC.

Regulatory Authorizations and Restrictions: Not available

**16. OTHER INFORMATION***Text of Symbol(s), R-phrase(s) and H-code(s) mentioned in Section 3*

	May form combustible dust concentrations in air (during processing).
F	Highly flammable
H228	Flammable solid
H302	Harmful if swallowed.
H340	May cause genetic defects.
H350	May cause cancer.
H360D	May damage the unborn child
H360F	May damage fertility
H372	Causes damage to organs through prolonged or repeated exposure.
R11	Highly flammable.
R22	Harmful if swallowed.
R45	May cause cancer.
R46	May cause heritable genetic damage.
R48	Danger of serious damage to health by prolonged exposure.
R60	May impair fertility.
R61	May cause harm to the unborn child.
T	Toxic

*Recommended Restrictions for Use:*

Not available

*SDS preparation information*

Prepared by	Research and Development Environment, Health and Safety 1-732-227-7380
Prepared on	06.03.2015 DD/MM/YYYY


This Safety Data Sheet was reformatted in accordance with the Globally Harmonized System of Classification and Labeling of Chemicals (GHS) for the United States of America (USA) (CFR 1910.1200), European Union (EU) (EC 1272/2008) and United Nations (UN).

*Other information*

HMIS	Health	1*
	Flammability	Not Determined (ND)
	Reactivity	Not Determined (ND)
	Personal protective equipment	See Section 8.

NFPA

Health	1
Fire	ND
Reactivity	ND
Special	ND



Country- Specific Emergency  
Phone Numbers

<b>CHEMTREC</b> In-Country Dial Numbers	Local # Provided in Country	Toll Free in Country*	Greeting Language
CHEMTREC South Africa*		0-800-983-611	English
CHEMTREC Argentina (Buenos Aires)	+(54)-1159839431		Latin American Spanish
CHEMTREC Brazil (Rio De Janeiro)	+(55)-2139581449		Portuguese
CHEMTREC Chile (Santiago)	+(56)-25814934		Latin American Spanish
CHEMTREC Colombia *		01800-710-2151	Latin American Spanish
CHEMTREC Mexico*		01-800-681-9531	Latin American Spanish
CHEMTREC Peru (Lima)	+(51)-17071295		Latin American Spanish
CHEMTREC China*	4001-204937		Mandarin
CHEMTREC Hong Kong (Hong Kong)*		800-968-793	Cantonese
CHEMTREC India *		000-800-100-7141	Hindi
CHEMTREC Indonesia*		001-803-017-9114	Indonesian
CHEMTREC Japan (Tokyo)	+(81)-345209637		Japanese
CHEMTREC Malaysia *		1-800-815-308	Malay
CHEMTREC Philippines *		1-800-1-116-1020	Tagalog
CHEMTREC Singapore*		800-101-2201	Mandarin
CHEMTREC Singapore	+(65)-31581349		Mandarin
CHEMTREC South Korea*		00-308-13-2549	Korean
CHEMTREC Taiwan*		00801-14-8954	Mandarin
CHEMTREC Thailand *		001-800-13-203-9987	Thai
CHEMTREC Vietnam (Ho Chi Minh City)	+(84)-838012436		Vietnamese
CHEMTREC Australia (Sydney)	+(61)-290372994		English
CHEMTREC Belgium (Brussels)	+(32)-28083237		French and Flemish
CHEMTREC Czech Republic (Prague)	+(420)-228880039		Czech
CHEMTREC France	+(33)-975181407		French
CHEMTREC Germany *		0800-181-7059	German
CHEMTREC Hungary (Budapest)	+(36)-18088425		Hungarian
CHEMTREC Italy *		800-789-767	Italian
CHEMTREC Italy (Milan)	+(39)-0245557031		Italian
CHEMTREC Netherlands	+(31)-858880596		Dutch
CHEMTREC Poland (Warsaw)	+(48)-223988029		Polish
CHEMTREC Spain*		900-868538	European Spanish
CHEMTREC Sweden (Stockholm)	+(46)-852503403		Swedish
CHEMTREC Switzerland (Zurich)	+(41)-435016715		German
CHEMTREC UK (London)	+(44)-870-8200418		English
CHEMTREC Bahrain (Bahrain)	+(973)-16199372		Arabic
CHEMTREC Israel (Tel Aviv)	+(972)-37630639		Hebrew

\*Phone numbers for countries marked with an asterisk must be dialed within the country

The information contained in this SDS is believed to be accurate and represents the best information reasonably available at the time of preparation. However, we make no warranty, express or implied, with respect to such information, and we assume no liability from its use.